Vaccination Against Ixodes scapularis Tick Bites

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,562.00
Award Year:
2001
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
54234
Agency Tracking Number:
1R43AI049651-01
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
BOX 8175, NEW HAVEN, CT, 94904
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
RAYMONDKOSKI
() -
Business Contact:
(203) 393-9439
MJMATT@IX.NETCOM.COM
Research Institute:
n/a
Abstract
Lyme disease is a multi-systemic infection and is caused by the pathogen Borrelia burgdorferi. The blacklegged tick, Ixodes scapularis, is the common vector for B. burgdorferi. The purpose of this project is to develop an anti-I. scapularis vaccine to block tick attachment and tick-mediated disease transmission. . Rabbits or guinea pigs infested with I. scapularis acquire antibody- mediated resistance to tick bites, a phenomenon known as "tick- immunity." We have developed a guinea pig model of host immunity against ticks. The tick-sensitized guinea pigs do not acquire Lyme disease when challenged with B. burgdorferi-infected I.. scapularis. Our plan is to determine which tick salivary gland antigens confer such host immunity, and subsequently produce them as recombinant antigens for evaluation as candidate vaccines. In preliminary experiments two recombinant proteins expressed from I. scapularis salivary gland cDNAs, Salp13 and Salp25D, induced tick-immunity. Phase I research will produce the recombinant proteins in prokaryotic and eukaryotic I expression systems. Guinea pigs and rabbits will be immunized with the purified antigens. We will then demonstrate host resistance to ticks, and inhibition of B. burgdorferi transmission from infected ticks. These experiments will lead to Phase II development of new vaccines to protect against multiple tick-borne pathogens. PROPOSED COMMERCIAL APPLICATIONS: A vaccine against Ixodes scapularis tick bites would potentially protect against several pathogens, including B. burgdorferi, the agent of human granulocytic ehrlichiosis, and Babesia microti. The commercial market would overlap with the market for LYMErix, a Lyme disease vaccine successfully sold by SmithKline Beecham.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government